- Home
- VIGL vs ASRT Comparison
VIGL vs ASRT Comparison
Compare VIGL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ASRT
- Stock Information
- Founded
- VIGL 2020
- ASRT 1995
- Country
- VIGL United States
- ASRT United States
- Employees
- VIGL N/A
- ASRT N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- ASRT Health Care
- Exchange
- VIGL Nasdaq
- ASRT Nasdaq
- Market Cap
- VIGL 74.7M
- ASRT 57.9M
- IPO Year
- VIGL 2022
- ASRT 1997
- Fundamental
- Price
- VIGL $2.41
- ASRT $0.64
- Analyst Decision
- VIGL Strong Buy
- ASRT Strong Buy
- Analyst Count
- VIGL 5
- ASRT 3
- Target Price
- VIGL $16.33
- ASRT $3.08
- AVG Volume (30 Days)
- VIGL 164.4K
- ASRT 313.4K
- Earning Date
- VIGL 05-07-2025
- ASRT 05-12-2025
- Dividend Yield
- VIGL N/A
- ASRT N/A
- EPS Growth
- VIGL N/A
- ASRT N/A
- EPS
- VIGL N/A
- ASRT N/A
- Revenue
- VIGL N/A
- ASRT $124,961,000.00
- Revenue This Year
- VIGL N/A
- ASRT N/A
- Revenue Next Year
- VIGL N/A
- ASRT $11.20
- P/E Ratio
- VIGL N/A
- ASRT N/A
- Revenue Growth
- VIGL N/A
- ASRT N/A
- 52 Week Low
- VIGL $1.31
- ASRT $0.51
- 52 Week High
- VIGL $6.06
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- VIGL 60.07
- ASRT 49.62
- Support Level
- VIGL $1.75
- ASRT $0.58
- Resistance Level
- VIGL $3.00
- ASRT $0.67
- Average True Range (ATR)
- VIGL 0.26
- ASRT 0.05
- MACD
- VIGL 0.08
- ASRT 0.01
- Stochastic Oscillator
- VIGL 55.30
- ASRT 40.82
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.